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Background: Patients with psoriasis may have an increased risk of developing atrial fibrillation (AF). We sought to determine whether this 
increased risk for AF is attributable to established risk factors.
Methods: All patients with and without psoriasis who underwent cardiac catheterization from 2005-2010 were identified using a nested-case 
control study design. Baseline demographics were obtained and electrocardiograms were reviewed for all subjects. The 10-year predicted risk for 
incident AF was calculated using the Framingham AF risk score.
Results: A total of 169 patients with psoriasis and without AF were age and gender-matched to control patients without a history psoriasis or 
AF. Patients with psoriasis had a higher BMI (31.5 ± 8 vs. 29.2 ± 7, p = 0.008) and higher baseline LDL (100 ± 35 vs. 92 ± 34, p = 0.04). Other 
baseline and electrocardiographic characteristics did not differ between patients with psoriasis and controls (Table). The 10-year estimated risk 
of incident AF was 12.8 ± 10.7% for patients with psoriasis and 14.7 ± 10.8 % for patients without psoriasis (p = 0.1). There was no association 
between psoriasis severity or duration and predicted risk of AF.
Conclusions: Current risk scores do not predict an increased risk for AF among patients with psoriasis. The increased incidence of AF among 
patients with psoriasis may not be captured in current risk scores. 
Variable
No psoriasis
(N = 169)
Psoriasis
(N = 169)
P value
Demographic Characteristics
Age, years 61 ± 11 61 ± 11 NS
Male (%) 99 (59) 99 (59) NS
BMI, kg/m2 29.2 ± 7 31.5 ± 8 0.008
Diabetes (%) 56 (33) 52 (31) 0.2
Active smoker 60 (36) 44 (27) 0.06
Systolic BP, mm Hg 134 ± 26 134 ± 24 0.9
Diastolic BP, mm Hg 74 ± 16 73 ± 15 0.6
Total cholesterol (mg/dl) 160 ± 40 167 ± 43 0.1
HDL (mg/dl) 41 ± 14 40 ± 14 0.6
LDL (mg/dl) 92 ± 34 100 ± 35 0.04
Triglycerides (mg/dl) 134 ± 78 144 ± 96 0.3
Significant murmur (%) 22 (13) 16 (10) 0.3
Treatment for hypertension (%) 141 (84) 128 (78) 0.1
Heart failure 42 (25) 34 (20) 0.3
Electrocardiographic Characteristics
PR interval (ms) 174 ± 36 169 ± 26 0.2
QRS duration (ms) 100 ± 26 98 ± 23 0.5
Left ventricular hypertrophy 31 (18) 28 (17) 0.7
Q waves 24 (14) 25 (15) 0.9
Left bundle branch block 10 (6) 10 (6) 1.0
Right bundle branch block 9 (5) 9 (5) 1.0
